![7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol](/upload/1124/V59611.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol does not have therapeutic targets. It is a genotoxic compound that targets DNA after metabolic activation. It is activated by hepatic cytosol into an electrophilic sulfuric acid ester, which then forms covalent DNA adducts. This interaction with DNA can lead to mutations, making it a compound of interest in toxicology and carcinogenesis research.
|
|---|---|
| ln Vitro |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is not evaluated for therapeutic activity. It is a genotoxic compound used in research on DNA damage and mutagenesis. It is activated by liver cytosol to form an electrophilic sulfate ester that can form covalent DNA adducts and induce mutations.
|
| ln Vivo |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is not used as a therapeutic compound. It is a research tool for studying genotoxicity and carcinogenesis. It is not administered to animals for therapeutic purposes.
|
| Enzyme Assay |
The genotoxic activity of 7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is assessed using in vitro mutagenicity assays such as the Ames test or by measuring DNA adduct formation. The compound is activated by liver cytosol (S9 fraction) to form electrophilic sulfate esters. DNA adduct formation can be detected by ³²P-postlabeling or mass spectrometry. Mutagenicity is assessed by measuring the reversion frequency in bacterial strains.
|
| Cell Assay |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is not used in cellular assays for therapeutic research. It is a genotoxic compound used in studies of DNA damage and mutagenesis. For cellular studies, cells are treated with the compound, and DNA adduct formation is measured. The compound has a molecular formula of C20H16O and a molecular weight of 272.34 g/mol. It is soluble in DMSO at 250 mg/mL (917.97 mM).
|
| Animal Protocol |
In vivo studies for 7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol are conducted in animal models to study its genotoxic and carcinogenic potential. The compound would be administered to rodents, and DNA adduct formation in various tissues would be assessed. However, specific published protocols for this compound are not detailed.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of 7-hydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene include 7,8,9,10-tetrahydrobenzo[a]pyrene-7-yl hydrogen sulfate. Pharmacokinetic data for 7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol are not extensively reported. The compound has a molecular formula of C20H16O and a molecular weight of 272.34 g/mol. It has a LogP of 5.01, indicating high lipophilicity. It is known to be metabolized by liver cytosol to an electrophilic sulfate ester. |
| Toxicity/Toxicokinetics |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is a genotoxic compound that forms covalent DNA adducts and induces mutations. It should be handled with extreme caution as a potential mutagen and carcinogen. Standard safety precautions for handling genotoxic compounds should be followed, including the use of appropriate personal protective equipment and containment.
|
| References |
|
| Additional Infomation |
7,8,9,10-Tetrahydrobenzo[pqr]tetraphen-7-ol is a benzopyrene analogue that is activated to a genotoxic electrophile capable of forming DNA adducts and inducing mutations. Molecular formula: C20H16O, molecular weight: 272.34 g/mol. No clinical applications exist. For research use only as a genotoxic standard.
|
| Molecular Formula |
C20H16O
|
|---|---|
| Molecular Weight |
272.34
|
| Exact Mass |
272.12
|
| CAS # |
6272-55-5
|
| PubChem CID |
97714
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
508.5±19.0 °C at 760 mmHg
|
| Melting Point |
142-144ºC(lit.)
|
| Flash Point |
189.2±13.7 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.836
|
| LogP |
5.01
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
21
|
| Complexity |
405
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VKUQFYXBPGXTKI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O/c21-18-6-2-5-15-16-10-9-13-4-1-3-12-7-8-14(11-17(15)18)20(16)19(12)13/h1,3-4,7-11,18,21H,2,5-6H2
|
| Chemical Name |
7,8,9,10-tetrahydrobenzo[a]pyren-7-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (917.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (7.64 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6719 mL | 18.3594 mL | 36.7188 mL | |
| 5 mM | 0.7344 mL | 3.6719 mL | 7.3438 mL | |
| 10 mM | 0.3672 mL | 1.8359 mL | 3.6719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
